The risk for death was higher than the risk for kidney failure until patients reached eGFRs less than 45 mL/min/1.73m2. When it comes to competing risks in patients with diabetes and chronic kidney ...

Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.

Hospitalized heart failure patients in the United States are living longer and receiving more optimized evidence-based care, according to new research drawn from nearly two decades of data in the ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide lowered the risk for worsening heart failure or CV death by 31% compared with placebo. The risk for ...

Share on Pinterest Scientists have discovered that the weight loss drug Zepbound may have benefits for heart failure patients. CR/Getty Images Heart failure is a serious condition that can often be a ...